All In Biotech

Drug Trial Radar · NCT07749911

Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)

Real-World Effectiveness of the R21/Matrix-M Malaria Vaccine in Children in Burkina Faso and Uganda

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Jul 14, 2026

Primary completion

Jun 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Clinton Health Access Initiative Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, San Francisco; Infectious Diseases Research Collaboration, Uganda; Institut de Recherche en Sciences de la Sante, Burkina Faso; Ministry of Health, Burkina Faso; Ministry of Health, Uganda
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 5 months, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21/Matrix-M vaccination program will be enrolled. Malaria infection will be determined by blood smear microscopy. Children with a positive microscopy result will be classified as cases and children with a negative result as controls. Vaccination history, including the number and timing of doses, will be obtained primarily from vaccination cards or other written records. Vaccine effectiveness will be estimated by comparing the odds of vaccination among cases and controls.

Conditions

  • Malaria
  • PLASMODIUM FALCIPARUM MALARIA

Interventions

  • R21/Matris-M Malaria vaccineBiological

    R21/Matrix-M vaccination received through routine national immunization programs. The study will record the number and dates of doses received. Children will be classified as having received 0, 1, 2, 3, or 4 eligible doses, with prespecified grouped classifications used if individual dose categories are underpowered. Doses given fewer than 14 days before malaria testing will not count toward the primary exposure classification.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-specific effectiveness of R21/Matrix-M against microscopy-confirmed clinical malariaTime frame: At the enrollment illness episode, during the approximately 7- to 8-month study recruitment period

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Boromo urbain 1

    Boromo, Boucle Mouhoun, Burkina Faso · Recruiting

  • Ouahabou

    Boromo, Boucle Mouhoun, Burkina Faso · Recruiting

  • Béréba

    Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Dohoun

    Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Kari

    Houndé, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Déguélin

    Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Karangasso-Vigué

    Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Sourmousso

    Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Wara

    Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso · Recruiting

  • Mankarga T

    Zorgo, Oubri, Burkina Faso · Recruiting

  • Mankarga V3

    Zorgo, Oubri, Burkina Faso · Recruiting

  • Mankarga V6

    Zorgo, Oubri, Burkina Faso · Recruiting

  • Kitgum-Matidi HCIII

    Kitgum, Acholi, Uganda · Not yet recruiting

  • Namokora HCIV

    Kitgum, Acholi, Uganda · Not yet recruiting

  • Lalogi HCIV

    Omoro, Acholi, Uganda · Not yet recruiting

  • Rwenyawawa HCIII

    Kikube, Bunyoro, Uganda · Not yet recruiting

  • Nawaikoke HCIII

    Kaliro, Busoga, Uganda · Not yet recruiting

  • Kigandalo HCIV

    Mayuge, Busoga, Uganda · Not yet recruiting

  • Nadunget HCIII

    Moroto, Karamoja, Uganda · Not yet recruiting

  • Orum HCIV

    Otuke, Lango, Uganda · Not yet recruiting

  • Otwal HCIII

    Oyam, Lango, Uganda · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.